Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Heart-lung transplantation at Papworth Hospital

Heart-lung transplantation at Papworth Hospital AbstractCombined heart-lung transplantation has been performed in 51 patientssince 1984. A pulmonary preservation fluid preceded by prostacyclininfusion has allowed distant procurement. Early organ function has beengood in all cases. Maintenance immunosuppression is cyclosporine andazathioprine. Steroids are given to treat rejection episodes.Transbronchial biopsy has allowed the accurate, early and safe diagnosis ofrejection. Acute cardiac rejection has not occurred in these patients.Thirty-seven patients are alive between 1 and 54 months followingtransplantation. The actuarial survival at 1 year is 76% and 68% at 2years. Four patients died in the early postoperative period as a result ofprimary Cytomegalovirus (CMV). Other causes of early death were bacterialinfection (4), cerebrovascular event (1), tracheal dehiscence (1) and smallbowel infarction following retransplantation for obliterativebronchiolitis. Three other patients have died as a result of obliterativebronchiolitis. Patients and donors have been carefully selected to ensurethat this scarce resource is utilised most effectively. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cardio-Thoracic Surgery Oxford University Press

Heart-lung transplantation at Papworth Hospital

European Journal of Cardio-Thoracic Surgery , Volume 3 (4) – Jul 1, 1989

Loading next page...
 
/lp/oxford-university-press/heart-lung-transplantation-at-papworth-hospital-TbI5O6FWon

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Oxford University Press
Copyright
© Springer-Verlag 1989
ISSN
1010-7940
eISSN
1873-734X
DOI
10.1016/1010-7940(89)90027-4
Publisher site
See Article on Publisher Site

Abstract

AbstractCombined heart-lung transplantation has been performed in 51 patientssince 1984. A pulmonary preservation fluid preceded by prostacyclininfusion has allowed distant procurement. Early organ function has beengood in all cases. Maintenance immunosuppression is cyclosporine andazathioprine. Steroids are given to treat rejection episodes.Transbronchial biopsy has allowed the accurate, early and safe diagnosis ofrejection. Acute cardiac rejection has not occurred in these patients.Thirty-seven patients are alive between 1 and 54 months followingtransplantation. The actuarial survival at 1 year is 76% and 68% at 2years. Four patients died in the early postoperative period as a result ofprimary Cytomegalovirus (CMV). Other causes of early death were bacterialinfection (4), cerebrovascular event (1), tracheal dehiscence (1) and smallbowel infarction following retransplantation for obliterativebronchiolitis. Three other patients have died as a result of obliterativebronchiolitis. Patients and donors have been carefully selected to ensurethat this scarce resource is utilised most effectively.

Journal

European Journal of Cardio-Thoracic SurgeryOxford University Press

Published: Jul 1, 1989

There are no references for this article.